Synthesis and clinical application of small-molecule inhibitors of Janus kinase
- 29 September 2023
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 261, 115848
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration (FLT3D835Y, JAK2V617F)
- Texas Air Research Center (59,60)
- European Commission (57,58)
- European Medicines Agency (49–51)
This publication has 90 references indexed in Scilit:
- Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosisBlood Cancer Journal, 2014
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaBlood Cancer Journal, 2011
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasmsBlood Cancer Journal, 2011
- Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces ApoptosisPLOS ONE, 2011
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- Therapeutic targeting of Janus kinasesImmunological Reviews, 2008
- Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera ProgenitorsCancer Cell, 2008
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia VeraCancer Cell, 2008